NCT07644650
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Start date changed from estimate of Nov 15, 2026 to Oct 26, 2026
Notable Recruitment opened Show 5 more changesShow less
- Start date: Jun 15, 2026 to Nov 15, 2026
- Primary endpoints: details revised at 1 of 2 entries
- Eligibility criteria expanded, about 2 words
- Study sites: 0 to 1
- Secondary endpoints: details revised at 2 of 16 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of dose-limiting toxicities (DLT)
Timeframe: Day 1 - Day 28
Incidence and severity of AEs, clinically significant changes from Baseline (pre-dose on D1) through to the EOT in vital signs, laboratory tests, physical examinations, 12-lead ECG, and ECHO/MUGA.
Timeframe: Through study completion, up to 25 months
Secondary (16)
PK parameters for MST-168, total anti-drug antibody and free payload: Tmax
PK parameters for MST-168, total anti-drug antibody and free payload: Cmax
PK parameters for MST-168, total anti-drug antibody and free payload: AUC0-t
PK parameters for MST-168, total anti-drug antibody and free payload: AUC0-∞
PK parameters for MST-168, total anti-drug antibody and free payload: t1/2
Show 11 moreShow less
PK parameters for MST-168, total anti-drug antibody and free payload: CL
PK parameters for MST-168, total anti-drug antibody and free payload: Vss
PK parameters for MST-168, total anti-drug antibody and free payload: AUCss
PK parameters for MST-168, total anti-drug antibody and free payload: Css,max
PK parameters for MST-168, total anti-drug antibody and free payload: Css,min
Frequencies of ADAs and neutralizing antibodies specific to MST-168.
Biomarkers: cytokines/chemokines and immune cell phenotypes
Objective response rate (ORR) based on RECIST v1.1.
Duration of response (DoR) based on RECIST v1.1.
Progression-free survival (PFS) based on RECIST v1.1.
Disease control rate (DCR) based on RECIST v1.1.
Arms and interventions
MST-168 initial dose level treatment CohortExperimental
MST-168 initial dose level
MST-168 dose level 2 treatment CohortExperimental
MST-168 dose level 2
MST-168 dose level 3 treatment CohortExperimental
MST-168 dose level 3
MST-168 dose level 4 treatment CohortExperimental
MST-168 dose level 4
MST-168 dose level 5 treatment CohortExperimental
MST-168 dose level 5
MST-168 dose level 6 treatment CohortExperimental
MST-168 dose level 6, if needed
Biologicals: MST-168
Sites
1 site in 1 country
- Shanghai Chest HospitalShanghai, Shanghai Municipality, China